BRIDGEWATER, N.J.–(BUSINESS WIRE)–Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate at the 2022 Jefferies Healthcare Conference held on June 8, 2022 in New York City. Mr. Patel will also be hosting a presentation which will begin at 8:00 … [Read more…]
FORT LEE, N.J.–(BUSINESS WIRE)–Luxa Biotechnology (LuxaBio), a joint venture between Y2 Solution Co. Ltd, Seoul, South Korea and the Neural Stem Cell Institute (NSCI), Rensselaer, New York, today announced transplantation of the cell product RPESC-RPE-4W into the first participant with dry age-related macular degeneration (dry AMD) in its Phase 1/2a clinical trial (NCT04627428) being conducted … [Read more…]
Conversational AI Pioneer Announces Executive Promotions Due to Continued Growth AKRON, Ohio–(BUSINESS WIRE)–Drips is pleased to announce the recent promotion of two of its top-level executives. In the past 12 months, Drips made tremendous strides in capturing market opportunities in key verticals such as healthcare, insurance, and financial services. The Drips team grew from 90 … [Read more…]
Selection Follows Post-Hoc Analysis Demonstrating Statistical Significance of Reproxalap Over Vehicle in Ocular Redness in Completed TRANQUILITY Trial LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the designation of Schirmer test, a measure of tear production, as the sole primary endpoint in the Phase 3 TRANQUILITY-2 clinical trial of reproxalap in patients with … [Read more…]
BRIDGEWATER, N.J. & VADODARA, India–(BUSINESS WIRE)–#abreva–Cosette Pharmaceuticals, Inc (“Cosette”), in collaboration with Aleor Dermaceuticals, a wholly owned subsidiary of Alembic Pharmaceuticals (“Alembic”; BSE: 533573), announced that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Application (ANDA) for an NBE version of Abreva® (Docosanol cream 10%) in a 2 gm tube … [Read more…]
– Lumasiran Demonstrated Evidence of Improvements in Exploratory Endpoints of Systemic Oxalosis, Including Echocardiographic Structure and Function, Nephrocalcinosis, and Kidney Stone Events – – Expands Upon Previously Reported Reductions in Plasma Oxalate in PH1 Patients with Severe Renal Impairment – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new … [Read more…]
The confirmatory clinical, safety and efficacy study for AVT04, biosimilar candidate to Stelara® (ustekinumab) met its primary endpoint AVT04 (ustekinumab) is part of a broader pipeline of Alvotech’s biosimilars and biosimilar candidates, which includes AVT02 (adalimumab), a biosimilar to Humira® Alvotech is the second company to announce positive top-line results from a patient study utilizing … [Read more…]
TAMPA, Fla.–(BUSINESS WIRE)–Edgility, Inc. launches EdgeAi as healthcare’s first operationally embedded AI with Explainability. EdgeAi exposes the internal mechanics of machine learning and deep learning systems in human-understandable terms. Trust in AI model predictions is paramount if care providers and administrators are to accept the decisions based on them. EdgeAi generates a standard label for … [Read more…]
NEW YORK–(BUSINESS WIRE)–Enhanced Healthcare Partners (“EHP”), a leading private equity firm focused on investing in middle-market businesses in the healthcare sector, is pleased to announce its strategic investment in Howard J. Chudler & Associates (“HCA”), a behavioral therapy services provider for people with autism and intellectual and developmental disabilities. Founded in 1983, HCA is headquartered … [Read more…]
– EFFICACY: In the pivotal Phase 3 clinical trial program, VTAMA cream met all primary and secondary endpoints and demonstrated highly statistically significant improvement versus vehicle in Physician Global Assessment (PGA) score with 36% of patients versus 6% in vehicle in PSOARING 1 and 40% of patients versus 6% in vehicle in PSOARING 2 achieving … [Read more…]
